BGM Group Ltd. (BGM)
About BGM Group Ltd.
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $25.1M
- Net income
- -$1.4M
- Total assets
- $53.0M
- Market cap
- $58.4M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $58.4M
- Shares outstanding
- 201.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 12, 2021
BGM Group Ltd. (BGM) Stock Price
- Reported a net loss of $1.4M in FY2024.
- Trading 98% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BGM Group Ltd..
Write a review
News about BGM Group Ltd.
News & sentiment via Polygon.io
BGM Group Ltd.: frequently asked questions
Is BGM Group Ltd. an American company?
BGM Group Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is BGM Group Ltd. publicly traded?
Yes — BGM Group Ltd. is a publicly traded company. Its stock trades under the ticker symbol BGM on the NASDAQ.
What does BGM Group Ltd. do?
BGM Group Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.
